Extended Duration Artemether-lumefantrine Treatment for Malaria in Children

PHASE4CompletedINTERVENTIONAL
Enrollment

305

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Uncomplicated Plasmodium Falciparum Malaria
Interventions
DRUG

Artemether-lumefantrine

Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.

Trial Locations (2)

Unknown

MGH campus, Busia

IDRC- Tororo Research Clinic and Tororo District Hospital, Tororo

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Yale University

OTHER

collaborator

Infectious Diseases Research Collaboration, Uganda

OTHER

lead

University of California, San Francisco

OTHER

NCT03453840 - Extended Duration Artemether-lumefantrine Treatment for Malaria in Children | Biotech Hunter | Biotech Hunter